3Lacono F, Barra S, De Ross, et al. Microstructureal disorders of tunica albuginea in patients affected by impotence. Eur Urol 1994; 26:233.
二级参考文献10
1[1]Porst H, et al. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 (suppl 1 ): S57-S64
2[2]Prost H, et al. The efficacy and tolerability of Vardenafil, a new, ora, selective PDE5 inhibitor, in patients with ED: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-199
3[3]Dula E, et al. Double-blind, crossover comparison of 3 mgapomorphine SL with placebo and with 4 mg apomorphine SL in male ED. Eur Urol 2001;39:558-564
4[4]Montorsi F, et al. Current status of local penile therapy.Int J Impot Res 2002;14(Suppl 1):S70-S81
5[5]AF De Rose, et al. Combined oral therapy with Sildenafil and doxazosin for the treatment of non-organic ED refractory to Sildenafil monotherapy. Int J Impot Res 2002;14:54-60
6[6]PI Lammers. Combination therapy for ED. Int J Impot Res 2002;14:54-58
7[7]Andersson KE, et al. The effect of Sidenafil on apomorphine evoked incresases in intracavernous pressure in the awake rat. J Urol 1999;161:1707-1712
8[8]Rees RW, et al. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavemosum. Br J Pharmacol 2001;133:455-458
9[9]Wohlfart P, et al. Release of nitric oxide from endothelial cells stimulated by YC-1,an activator of soluble guanylyl cyclase. Br J Pharmacol 1999;128:1316-1322
10[10]Byrne RR, et al. VEGF restores corporeal smooth muscle function in vitro. J Urol 2001;165:1310-1315
